
As proposed by its Advisory Committee on Immunization Practices, the Centers for Disease Control and Prevention today recommended a single dose of the GSK or Pfizer Respiratory Syncytial Virus vaccine for people aged 60 and older who decide with their health care provider that the vaccine would benefit them.